IL264961A - - Google Patents
Info
- Publication number
- IL264961A IL264961A IL26496119A IL26496119A IL264961A IL 264961 A IL264961 A IL 264961A IL 26496119 A IL26496119 A IL 26496119A IL 26496119 A IL26496119 A IL 26496119A IL 264961 A IL264961 A IL 264961A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378391P | 2016-08-23 | 2016-08-23 | |
| PCT/EP2017/071106 WO2018037001A1 (en) | 2016-08-23 | 2017-08-22 | Anti-vegf-a antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264961A true IL264961A (https=) | 2019-04-30 |
| IL264961B1 IL264961B1 (en) | 2024-10-01 |
| IL264961B2 IL264961B2 (en) | 2025-02-01 |
Family
ID=59677248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264961A IL264961B2 (en) | 2016-08-23 | 2017-08-22 | Antibodies against VEGF–A and their uses |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10919958B2 (https=) |
| EP (2) | EP3783022B1 (https=) |
| JP (2) | JP6949106B2 (https=) |
| KR (1) | KR102538827B1 (https=) |
| CN (1) | CN109863172B (https=) |
| AU (2) | AU2017315076B2 (https=) |
| ES (1) | ES2836286T3 (https=) |
| IL (1) | IL264961B2 (https=) |
| WO (1) | WO2018037001A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7485273B2 (ja) * | 2020-06-25 | 2024-05-16 | 国立大学法人 鹿児島大学 | 抗ｖｅｇｆ－ａ抗体による癌に対する治療応答性を予測又は決定するための方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| KR100816621B1 (ko) * | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| PT971959E (pt) * | 1997-04-07 | 2006-05-31 | Genentech Inc | Anticorpos humanizados e metodos para formar anticorpos humanizados |
| ES2252261T3 (es) | 2000-06-28 | 2006-05-16 | Glycofi, Inc. | Metodos para producir glicoproteinas modificadas. |
| JP2009526520A (ja) | 2006-01-17 | 2009-07-23 | バイオレックス セラピュティックス インク | 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法 |
| JP2010507594A (ja) * | 2006-10-20 | 2010-03-11 | シェーリング コーポレイション | 完全ヒト抗ｖｅｇｆ抗体および使用方法 |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| WO2010124009A2 (en) * | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| CN102276722B (zh) * | 2011-01-14 | 2013-05-08 | 中国科学院北京基因组研究所 | 新型血管内皮生长因子人源化单克隆抗体 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US9580509B2 (en) * | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
-
2017
- 2017-08-22 IL IL264961A patent/IL264961B2/en unknown
- 2017-08-22 KR KR1020197007757A patent/KR102538827B1/ko active Active
- 2017-08-22 EP EP20189960.6A patent/EP3783022B1/en active Active
- 2017-08-22 AU AU2017315076A patent/AU2017315076B2/en active Active
- 2017-08-22 WO PCT/EP2017/071106 patent/WO2018037001A1/en not_active Ceased
- 2017-08-22 US US16/327,362 patent/US10919958B2/en active Active
- 2017-08-22 EP EP17754722.1A patent/EP3504236B1/en active Active
- 2017-08-22 ES ES17754722T patent/ES2836286T3/es active Active
- 2017-08-22 CN CN201780064561.XA patent/CN109863172B/zh active Active
- 2017-08-22 JP JP2019510850A patent/JP6949106B2/ja active Active
-
2020
- 2020-12-18 AU AU2020289850A patent/AU2020289850B2/en active Active
-
2021
- 2021-01-19 US US17/152,409 patent/US11634483B2/en active Active
- 2021-09-21 JP JP2021152836A patent/JP7277531B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL264961B2 (en) | 2025-02-01 |
| CN109863172B (zh) | 2022-08-26 |
| JP2019528074A (ja) | 2019-10-10 |
| AU2017315076B2 (en) | 2020-10-08 |
| EP3783022A2 (en) | 2021-02-24 |
| EP3504236B1 (en) | 2020-09-23 |
| US10919958B2 (en) | 2021-02-16 |
| AU2020289850B2 (en) | 2024-06-06 |
| CA3034576A1 (en) | 2018-03-01 |
| WO2018037001A1 (en) | 2018-03-01 |
| AU2020289850A1 (en) | 2021-01-28 |
| AU2017315076A1 (en) | 2019-04-04 |
| US20210147531A1 (en) | 2021-05-20 |
| KR102538827B1 (ko) | 2023-05-31 |
| US11634483B2 (en) | 2023-04-25 |
| JP2022008447A (ja) | 2022-01-13 |
| IL264961B1 (en) | 2024-10-01 |
| JP6949106B2 (ja) | 2021-10-13 |
| EP3504236A1 (en) | 2019-07-03 |
| CN109863172A (zh) | 2019-06-07 |
| US20190202903A1 (en) | 2019-07-04 |
| JP7277531B2 (ja) | 2023-05-19 |
| EP3783022B1 (en) | 2026-03-04 |
| KR20190040029A (ko) | 2019-04-16 |
| EP3783022A3 (en) | 2021-06-30 |
| ES2836286T3 (es) | 2021-06-24 |